SCHEMBL1754078

SCHEMBL1754078

COc1ccccc1NC(=O)C(C(=O)Nc1ccccc1)c1ccc(C(=O)Nc2ccc(-c3ccccc3)cc2N)cc1

nearest known ligand 0.71

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 16/20 0.71
HDAC3 O15379 7/20 0.62
HDAC2 Q92769 7/20 0.62
ABCB1 P08183 1/20 0.58
ABCC1 P33527 1/20 0.57
KMT2A Q03164 1/20 0.52
NCOR2 Q9Y618 6/20 0.50
HDAC8 Q9BY41 1/20 0.48
HDAC6 Q9UBN7 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1689223 0.93 HDAC1 (0.71) HDAC1HDAC3HDAC2KMT2A
SCHEMBL1689265 0.89 HDAC1 (0.89) HDAC1HDAC3HDAC2NCOR2HDAC8
SCHEMBL1689251 0.84 HDAC1 (1.00) HDAC1HDAC3HDAC2NCOR2HDAC8
SCHEMBL2108411 0.81 HDAC1 (0.74) HDAC1HDAC3HDAC2
SCHEMBL1689190 0.81 HDAC1 (0.74) HDAC1HDAC3HDAC2NCOR2
SCHEMBL2108136 0.80 HDAC1 (0.96) HDAC1HDAC3HDAC2KMT2ANCOR2
SCHEMBL1754325 0.78 HDAC1 (1.00) HDAC1HDAC3HDAC2NCOR2
SCHEMBL1689052 0.77 HDAC1 (1.00) HDAC1HDAC3HDAC2KMT2ANCOR2
SCHEMBL2108404 0.77 HDAC1 (0.74) HDAC1HDAC3HDAC2HDAC8HDAC6
SCHEMBL1689174 0.77 HDAC1 (0.67) HDAC1HDAC3HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1896395-B1 MODIFIED MALONATE DERIVATIVES MERCK SHARP & DOHME (US) 2015-07-15 EP disclosed
US-8158825-B2 Modified malonate derivatives MERCK SHARP & DOHME CORP. (US) 2012-04-17 US disclosed
US-8158825-B2 Modified malonate derivatives MERCK SHARP & DOHME CORP. (US) 2012-04-17 US disclosed
US-8158825-B2 Modified malonate derivatives MERCK SHARP & DOHME CORP. (US) 2012-04-17 US disclosed
US-20100160327-A1 Modified Malonate Derivatives MERCK SHARP & DOHME LLC 2010-06-24 US disclosed
US-20100160327-A1 Modified Malonate Derivatives MERCK SHARP & DOHME LLC 2010-06-24 US disclosed
US-20100160327-A1 Modified Malonate Derivatives MERCK SHARP & DOHME LLC 2010-06-24 US disclosed
EP-1896395-A2 MODIFIED MALONATE DERIVATIVES Merck & Co., Inc. (US) 2008-03-12 EP disclosed
WO-2007002248-A2 MODIFIED MALONATE DERIVATIVES MERCK & CO., INC. (US) 2007-01-04 WO disclosed
WO-2007002248-A2 MODIFIED MALONATE DERIVATIVES MERCK & CO., INC. (US) 2007-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160327-A1 Modified Malonate Derivatives ME2, ME3, ME1 HDAC1 6/4885HDAC3 17/4885HDAC2 42/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.